Medexus Pharmaceuticals Inc (P731) Stock Price & Analysis
P731 Stock Chart & Stats
- Day’s Range
- EUR 3.16 - EUR 3.16
- 52-Week Range
- EUR 1.51 - EUR 3.34
- Previous Close
- EUR 3.10
- Volume
- 0
- Average Volume (3M)
- 33
- Market Cap
- EUR 98.94M
- Enterprise Value
- EUR 192.00M
- Total Cash (Recent Filing)
- EUR 5.34M
- Total Debt (Recent Filing)
- EUR 26.21M
- Price to Earnings (P/E)
- ―
- Beta
- 0.98
- Next Earnings
- Nov 11, 2026 (Est.)
- EPS Estimate
- 0.02
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
GRAFAPEX Adoption
Broad institutional uptake and repeat ordering indicate durable product acceptance rather than one-time stocking. Continued patient-demand growth can support recurring revenue and strengthen Medexus’s position in specialty hospital care.
Revenue And EBITDA Growth
Improving revenue, EBITDA and operating income show operating leverage as commercialization scales. If sustained, this progress can improve the company’s earnings quality and provide greater capacity to fund product expansion.
Portfolio Expansion
Adding UM171 expands the hematology and cell-therapy portfolio and leverages Medexus’s existing allo-HSCT commercial expertise. A potential expedited Canadian regulatory path could create another durable growth opportunity beyond current products.
Bears Say
Persistent Net Losses
Despite positive gross and operating margins, recurring net losses indicate that the business has not yet converted commercialization activity into durable bottom-line profitability. Negative ROE also shows the equity base remains underproductive.
Weak Cash Conversion
Negative trailing free cash flow limits financial flexibility and makes growth more dependent on working-capital management or external funding. The deterioration from the prior year suggests current expansion is absorbing cash before benefits fully mature.
Product Concentration And Competition
Dependence on GRAFAPEX concentrates execution risk in one growth product, while generic competition for Rasuvo and possible tariffs could pressure revenue or margins. These factors may make the portfolio’s long-term performance less predictable.
Medexus Pharmaceuticals Inc News
P731 FAQ
What was Medexus Pharmaceuticals Inc’s price range in the past 12 months?
What is Medexus Pharmaceuticals Inc’s market cap?
When is Medexus Pharmaceuticals Inc’s upcoming earnings report date?
How were Medexus Pharmaceuticals Inc’s earnings last quarter?
Is Medexus Pharmaceuticals Inc overvalued?
Does Medexus Pharmaceuticals Inc pay dividends?
What is Medexus Pharmaceuticals Inc’s EPS estimate?
How many shares outstanding does Medexus Pharmaceuticals Inc have?
What happened to Medexus Pharmaceuticals Inc’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Medexus Pharmaceuticals Inc?
What is the TipRanks Smart Score and how is it calculated?
Medexus Pharmaceuticals Inc Stock Smart Score
Company Description
Medexus Pharmaceuticals Inc
Medexus Pharmaceuticals Inc. operates as a pharmaceutical company in Canada and the United States. The company focuses on various therapeutic areas comprising allergy, dermatology, hematology, oncology, rheumatology, and rare diseases. Its primary products include IXINITY, an intravenous recombinant factor IX therapeutic for use in patients with hemophilia B; Rasuvo and Metoject, a formulation of methotrexate designed to treat rheumatoid arthritis and other auto-immune diseases; Rupall, a prescription allergy medication; GRAFAPEX, an injection to treat allogeneic hematopoietic stem cell transplantation in adult and pediatric patients, acute myeloid leukemia (AML), and myelodysplastic syndrome (MDS); and Gleolan, an optical imaging agent for patients with glioma as an adjunct for the visualization of malignant tissue during surgery. The company’s products portfolio also includes Cuvposa, a glycopyrrolate oral solution; Naproxen, a Pediapharm naproxen suspension; Otixal, a ciprofloxacin and flucinolone acetonide; Trispan, a triamcinolone hexacetonide injectable suspension; and Trecondyv, a bifunctional alkylating agent for use as part of a conditioning treatment for patients undergoing allogeneic hematopoietic stem cell transplantation. In addition, it offers over the counter products comprising Nyda, a topical treatment indicated for the eradication of head lice; Relaxa, an osmotic laxative to treat occasional constipation in adults; Oralvisc to reduce joint pain and enhance joint function in osteoarthritis of the knee; and Calcia Calcium and vitamin D products. The company was formerly known as Pediapharm Inc. and changed its name to Medexus Pharmaceuticals Inc. in December 2018. Medexus Pharmaceuticals Inc. was founded in 2000 and is based in Toronto, Canada.
- Sector
- Healthcare
- Industry
- Medical - Pharmaceuticals
- CEO
- Kenneth d'Entremont
- Employees
- 90
- Website
- www.medexus.com
- Address
- 10 King Street East, Toronto, ON, M5C 1C3, CA
Medexus Pharmaceuticals Inc (P731) Earnings & Revenues
P731 Earnings Call
Earnings Call SentimentPositive
The call highlights substantial commercial momentum for GRAFAPEX (strong quarter, double-digit demand growth vs prior year, repeat ordering, and reiterated near- and long-term revenue targets) and measurable improvements in revenue, adjusted EBITDA and gross profit. Offsetting items include a negative swing in operating cash flow driven by working capital timing, a $5.2M increase in net debt, modest margin compression caused by prior-year comparatives, higher SG&A, and product-level risks (Rasuvo ANDA/tariff uncertainty and concentration of growth in GRAFAPEX). On balance, the positives around product adoption, revenue growth and EBITDA expansion materially outweigh the manageable near-term cash and leverage headwinds.
View all DE:P731 earnings summariesP731 Stock 12 Month Forecast
Average Price Target
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 16 | 1 | 4 |
| Technical Analysis | 4 | 1 | 4 |
| Moving Averages | 12 | 0 | 0 |